Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bioverativ buys rare blood disease firm

by Lisa M. Jarvis
May 29, 2017 | A version of this story appeared in Volume 95, Issue 22

Seeking to become a leader in treating blood disorders, Bioverativ will pay $400 million up front to acquire privately held True North Therapeutics. Bioverativ, a Biogen spin-off, adds to its portfolio TNT009, a monoclonal antibody in early-stage studies for cold agglutinin disease, a rare form of anemia that occurs when autoantibodies attack red blood cells. True North investors could see another $425 million in milestone payments if TNT009 reaches the market.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.